{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:51:15Z","timestamp":1791982275401,"version":"4.4.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggest almost one-third of myeloma patients acquire genetic alteration of the key IMiD effector cereblon (CRBN) by the time they are pomalidomide refractory. Some events, including stop codons\/frameshift mutations and copy loss, have clearly explicable effects on CRBN protein function. Missense mutations have also been reported throughout the length of CRBN but their functional impact has not been systematically studied. This study modeled selected missense mutations and examined their effect on CRBN function also analyzing whether any mutations deleterious to IMiD action could be overcome using the novel cereblon E3 ligase modulators (CELMoDs). Three patterns of response to missense mutations were apparent: mutations that led to complete loss of CRBN function for all agents, those that had no effect on CRBN function, and those with agent-dependent effect on CRBN function. The latter group of 4 mutations were profiled in more detail with confirmatory experiments demonstrating an ability of the more potent CELMoDs to lead to neosubstrate degradation and cell death even though IMiDs were not active. Dynamic modeling based on a newly generated crystal structure of the DDB1\/CRBN\/lenalidomide complex, with greater resolution than those published to date, helped to understand the impact of these mutations. These results have important implications for the interpretation of CRBN sequencing results from patients for future therapy decisions, particularly differentiating those who may, despite relapsing on IMiDs with CRBN mutations, have the potential to still benefit from the use of CELMoD agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025861","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:28:42Z","timestamp":1737545322000},"page":"2630-2644","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Evaluating the impact of\n                    <i>CRBN<\/i>\n                    mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2831-1321","authenticated-orcid":false,"given":"Yakinthi","family":"Chrisochoidou","sequence":"first","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3287-6210","authenticated-orcid":false,"given":"Andrea","family":"Scarpino","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Morales","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-0937","authenticated-orcid":false,"given":"Sarah","family":"Bird","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"},{"name":"2Department of Haematology, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-214X","authenticated-orcid":false,"given":"Yigen","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-6254","authenticated-orcid":false,"given":"Brian","family":"Walker","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9141-5452","authenticated-orcid":false,"given":"John","family":"Caldwell","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-9706","authenticated-orcid":false,"given":"Yann-Va\u00ef","family":"Le Bihan","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0028","authenticated-orcid":false,"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom"},{"name":"2Department of Haematology, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2025052911214564000_bib1","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025052911214564000_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"issue":"4","key":"2025052911214564000_bib3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"2025052911214564000_bib4","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"issue":"11","key":"2025052911214564000_bib5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2025052911214564000_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/leu.2013.315","article-title":"Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy","volume":"28","author":"Thakurta","year":"2014","journal-title":"Leukemia"},{"issue":"5971","key":"2025052911214564000_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"7","key":"2025052911214564000_bib8","doi-asserted-by":"crossref","first-page":"e941742","DOI":"10.4161\/21624011.2014.941742","article-title":"Lenalidomide induces degradation of IKZF1 and IKZF3","volume":"3","author":"Kr\u00f6nke","year":"2014","journal-title":"OncoImmunology"},{"issue":"5","key":"2025052911214564000_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"issue":"7597","key":"2025052911214564000_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4 CRBN ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"issue":"6619","key":"2025052911214564000_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"issue":"6414","key":"2025052911214564000_bib12","doi-asserted-by":"crossref","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"issue":"7512","key":"2025052911214564000_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"issue":"9","key":"2025052911214564000_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"2025052911214564000_bib15","doi-asserted-by":"crossref","first-page":"e1004023","DOI":"10.1371\/journal.pcbi.1004023","article-title":"The thalidomide-binding domain of cereblon defines the CULT domain family and is a new member of the \u03b2-tent fold","volume":"11","author":"Lupas","year":"2015","journal-title":"PLoS Comput Biol"},{"issue":"7933","key":"2025052911214564000_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41586-022-05333-5","article-title":"The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron","volume":"10","author":"Ichikawa","year":"2022","journal-title":"Nature"},{"issue":"7611","key":"2025052911214564000_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4 CRBN ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"4","key":"2025052911214564000_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","article-title":"Crystal structure of the SALL4\u2013pomalidomide\u2013cereblon\u2013DDB1 complex","volume":"27","author":"Matyskiela","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"2025052911214564000_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41589-021-00802-w","article-title":"Acute pharmacological degradation of Helios destabilizes regulatory T cells","volume":"17","author":"Wang","year":"2021","journal-title":"Nat Chem Biol"},{"issue":"7201","key":"2025052911214564000_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"23","key":"2025052911214564000_bib21","doi-asserted-by":"crossref","first-page":"eabg2697","DOI":"10.1126\/sciadv.abg2697","article-title":"ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"issue":"4","key":"2025052911214564000_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2025052911214564000_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2025052911214564000_bib24","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1158\/1078-0432.CCR-21-3695","article-title":"Myeloma genome project panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma","volume":"28","author":"Sudha","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025052911214564000_bib25","unstructured":"The PyMOL Molecular Graphics System. Version 2.5.5. Schr\u00f6dinger, LLC;. 2023. Accessed 5 June 2024. https:\/\/pymol.org."},{"issue":"9","key":"2025052911214564000_bib26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025052911214564000_bib27","doi-asserted-by":"crossref","first-page":"E237","DOI":"10.3324\/haematol.2019.217943","article-title":"IKZF1\/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma","volume":"105","author":"Barrio","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"2025052911214564000_bib28","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1038\/s41375-021-01373-4","article-title":"Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs","volume":"35","author":"Jones","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2025052911214564000_bib29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.12291","article-title":"Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease","volume":"161","author":"Egan","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2025052911214564000_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"2025052911214564000_bib31","unstructured":"Schr\u00f6dinger Suite v2023-3. Schr\u00f6dinger, LLC; 2023. Accessed 5 June 2024. https:\/\/www.schrodinger.com\/."},{"key":"2025052911214564000_bib32","doi-asserted-by":"crossref","unstructured":"Bowers\n              KJ\n            , ChowE, XuH, . Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the ACM\/IEEE Conference on Supercomputing (SC06); 11-17 November 2006; Tampa, FL. Accessed 5 June 2024. https:\/\/dl.acm.org\/doi\/proceedings\/10.1145\/1188455.","DOI":"10.1145\/1188455.1188544"},{"key":"2025052911214564000_bib33","unstructured":"Molecular Operating Environment. Chemical Computing Group; 2024. Accessed 5 June 2024. https:\/\/www.chemcomp.com\/."},{"issue":"3","key":"2025052911214564000_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12185-016-2073-4","article-title":"Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs","volume":"104","author":"Ito","year":"2016","journal-title":"Int J Hematol"},{"issue":"3","key":"2025052911214564000_bib35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41589-022-01177-2","article-title":"Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders","volume":"19","author":"Hanzl","year":"2023","journal-title":"Nat Chem Biol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024025861\/2376658\/blood_bld-2024-025861-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024025861\/2376658\/blood_bld-2024-025861-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:21:57Z","timestamp":1748517717000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/22\/2630\/535234\/Evaluating-the-impact-of-CRBN-mutations-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":35,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,5,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025861","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,29]]},"published":{"date-parts":[[2025,5,29]]}}}